Cellular Dynamics, the stem cell company founded by Dr. James Thomson, is filing for an IPO. Hat tip to David Jensen.
The company, which will go under the stock symbol ICEL, is focused on iPS cell-produced products. They describe their portfolio as follows:
Cellular Dynamics is developing and deploying a number of cell types derived from induced pluripotent stem (iPS) cells in additional to providing custom services to aid in life science research and drug discovery.
If you recall, both Thomson and Dr. Shinya Yamanaka both produced human iPS cells using related, but somewhat different reprogramming factors. Yamanaka produced mouse iPS cells an entire year earlier than that, well before anyone else.
A recent question is the issue of who has the intellectual property (IP) rights to iPS cell technology. People have told me in the past that they wondered if Cellular Dynamics has unambiguous rights to develop all of these iPS cell-based products.
The Cellular Dynamics IPO is going to be for up to $57 million. The full filing can be read here.
This IPO filing is intriguing in that it indicates a licensing agreement to the Yamanaka-related patents:
I find it very interesting that this licensing was deemed necessary. Other labs developing iPS cell-related technologies should take heed that even Thomson’s company decided it had to get licensing from Yamanaka although Thomson has been an innovator on iPS cells too.
Trade secrets are frequently mentioned in the IPO filing.
This looks to be very interesting and could transform the field as it develops. I’ve only scratched the surface of reading this very long, detail rich IPO filing, which likely has a lot more in the way of interesting nuggets.